ArticleBMC musculoskeletal disorders2025
A case report of dermatofibrosarcoma protuberans with osteolytic.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDermatofibrosarcoma protuberans (DFSP) is a rare, low-to-intermediate grade malignant soft tissue sarcoma that is prone to local recurrence after surgery but rarely metastasizes to distant sites. However, in this case, the tumor metastasized to the humerus and presented as a solitary lesion. CASE PRESENTATION: A 42-year-old male patient presented with pain and limited mobility in the left upper limb, with a history of surgery for DFSP in the popliteal fossa. Imaging examinations revealed bone destruction in the proximal humerus and a soft tissue mass, with the lesion measuring 11.0 × 8.5 × 7.0 cm. Aspiration biopsy confirmed that the lesion in the humerus was a metastatic tumor. After two months of palliative treatment, follow-up examinations showed a reduction in the size of the lesion.Seven months after the treatment, the humeral lesion had progressed, and multiple new bone metastases were found.
conclusionsMetastasis of DFSP is rare, and bone metastasis is even rarer. We need to integrate medical history, perform comprehensive diagnosis through immunohistochemistry, molecular pathology monitoring, and imaging examinations. Additionally, this case reminds us that when encountering patients who primarily complain of bone pain during the initial diagnosis, we should thoroughly inquire about their medical and surgical history, conduct a comprehensive analysis, and make an integrated judgment. When necessary, perform a core biopsy first to determine the origin of the lesion. This approach allows us to provide patients with as comprehensive a range of treatment options as possible, thereby improving their quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.